ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent claims contain both composition and method of treatment claims that will broadly cover all of InSite’s bromfenac product candidates, including BromSite™ ((bromfenac 0.075%) ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite’s pipeline that will be covered under this patent include: ISV-101 (bromfenac (0.01% to 0.04%) ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as bromfenac and dexamethasone containing products such as BromDex (ISV-504). The patent is expected to provide protection for bromfenac formulations in DuraSite to 2029.
Help employers find you! Check out all the jobs and post your resume.
